Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi
therapeutics company, today announced the pricing of an underwritten
registered public offering of 8,000,000 shares of its common stock at a
public offering price of $20.13 per share. All of the shares in the
offering are to be sold by Alnylam. The offering is expected to close on
or about January 22, 2013, subject to the satisfaction of customary
closing conditions.
J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as
joint book-running managers and representatives of the underwriters for
the offering. Deutsche Bank Securities Inc., Piper Jaffray & Co.,
Leerink Swann LLC, Needham & Company, LLC and JMP Securities LLC are
acting as co-managers for the offering. Alnylam has granted the
underwriters a 30-day option to purchase up to 1,200,000 shares to cover
overallotments, if any.
The securities described above are being offered by Alnylam pursuant to
an automatically effective shelf registration statement that Alnylam
previously filed with the Securities and Exchange Commission (SEC).
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor shall there be any
sale of these securities in any state in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under
the securities laws of such state. A preliminary prospectus supplement
related to the offering has been filed with the SEC. Before you invest,
you should read the prospectus and the related prospectus supplement and
any other document Alnylam has filed with the SEC for more complete
information about Alnylam and this offering. You may get these documents
for free by visiting EDGAR on the SEC Website at www.sec.gov.
Alternatively, copies of the prospectus and the prospectus supplements
relating to this offering may be obtained by contacting J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717 (telephone: 866-803-9204); or Morgan
Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014 (telephone: 866-718-1649, email: prospectus@morganstanley.com).
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical
company developing novel therapeutics based on RNA interference, or
RNAi. The company is leading the translation of RNAi as a new class of
innovative medicines with a core focus on RNAi therapeutics for the
treatment of genetically defined diseases, including ALN-TTR for the
treatment of transthyretin-mediated amyloidosis (ATTR), ALN-AT3 for the
treatment of hemophilia and rare bleeding disorders (RBD), ALN-AS1 for
the treatment of acute intermittent porphyria, ALN-PCS for the treatment
of severe hypercholesterolemia, and ALN-TMP for the treatment of
hemoglobinopathies. As part of its “Alnylam 5x15™” strategy, the company
expects to have five RNAi therapeutic products for genetically defined
diseases in clinical development, including programs in advanced stages,
on its own or with a partner by the end of 2015. Alnylam has additional
partnered programs in clinical or development stages, including
ALN-RSV01 for the treatment of respiratory syncytial virus (RSV)
infection and ALN-VSP for the treatment of liver cancers. The company’s
leadership position on RNAi therapeutics and intellectual property have
enabled it to form major alliances with leading companies including
Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko
Kirin, Cubist, Ascletis, Monsanto and Genzyme. In addition, Alnylam
holds a significant equity position in Regulus Therapeutics Inc., a
company focused on discovery, development, and commercialization of
microRNA therapeutics. Alnylam has also formed Alnylam Biotherapeutics,
a division of the company focused on the development of RNAi
technologies for applications in biologics manufacturing, including
recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™
platform applies RNAi technology to improve the manufacturing processes
for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam
scientists and collaborators have published their research on RNAi
therapeutics in over 100 peer-reviewed papers, including many in the
world’s top scientific journals such as Nature, Nature Medicine,
Nature Biotechnology, and Cell. Founded in 2002, Alnylam
maintains headquarters in Cambridge, Massachusetts.
Alnylam Forward-Looking Statements
Statements in this
release concerning Alnylam’s future expectations, plans and prospects
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including risks related to fluctuations in our stock price, those
associated with market conditions and the satisfaction of customary
closing conditions related to the proposed offering, as well as those
risks more fully discussed in the “Risk Factors” filed with Alnylam’s
current report on Form 8-K filed with the SEC on January 14, 2013 and in
other filings that Alnylam makes with the SEC. There can be no assurance
that Alnylam will be able to complete the proposed public offering on
the anticipated terms, or at all. You should not place undue reliance on
these forward-looking statements. In addition, any forward-looking
statements represent Alnylam’s views only as of today and should not be
relied upon as representing Alnylam’s views as of any subsequent date.
Alnylam disclaims any obligation to update any forward-looking
statements.
